Eflornithine supplier | CasNO.70052-12-9

Name
DFMO
EINECS
CAS No. 70052-12-9
Article Data5
CAS DataBase
Density 1.293g/cm³
Solubility
Melting Point 138 °C
Formula C₆H₁₂F₂N₂O₂
Boiling Point 347 °C at 760 mmHg
Molecular Weight 182.17
Flash Point 163.7 °C
Transport Information
Appearance
Safety
Risk Codes
Molecular Structure
Hazard Symbols
Synonyms 2-(Difluoromethyl)-DL-ornithine;2-(Difluoromethyl)ornithine;DFMO;DFMO (growth regulator);DL-2-(Difluoromethyl)ornithine;DL-a-(Difluoromethyl)ornithine;Elfornithine;Ornidyl;a,d-Diamino-a-(difluoromethyl)valericacid;a-(Difluoromethyl)-DL-ornithine;a-(Difluoromethyl)ornithine;
PSA 89.34000
LogP 1.17310

Eflornithine Chemical Properties

IUPAC Name: 2,5-diamino-2-(difluoromethyl)pentanoic acid
Molecular Formula: C₆H₁₂F₂N₂O₂
Molar mass: 182.1685 g/mol
EINECS: 222-760-4
Density: 1.293 g/cm³
Flash Point: 163.7 °C
Index of Refraction: 1.462
Boiling Point: 347 °C at 760 mmHg
Vapour Pressure: 9.72E-06 mmHg at 25°C
Storage temp: Store at 0 °C
Solubility: H₂O >10 mg/mL, soluble
Form: Solid
Color: White
Product categories: facial hair remover
Structure of Eflornithine (CAS NO.70052-12-9):

XLogP3-AA: -2.9
H-Bond Donor: 3
H-Bond Acceptor: 6
IUPAC Name: 2,5-Diamino-2-(difluoromethyl)pentanoic acid
Canonical SMILES: C(CC(C(F)F)(C(=O)O)N)CN
InChI: InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,
12)
InChIKey: VLCYCQAOQCDTCN-UHFFFAOYSA-N

Eflornithine Uses

Eflornithine (CAS NO.70052-12-9) is a drug manufactured by Sanofi-Aventis that has various uses. A recent study (reported 2008 ) conducted by UC Irvine researchers indicates that, when combined with sulindac , Eflornithine significantly reduces the risk of recurring colorectal polyps. It was initially developed for cancer treatment, but, while having little use in treating malignancies. In the United States it is known by the brand name Ornidyl.

Eflornithine Production

Eflornithine (CAS NO.70052-12-9), its production was halted by its manufacturer, Aventis, in 1995 because the company did not consider it a profitable drug. In 2001, after lobbying at the WHO World Health Organization by Médecins Sans Frontières ("Doctors Without Borders"), the manufacturer resumed production of eflornithine, melarsoprol, and pentamidine in sufficient amounts to cover existing needs. As of September 2005, the World Health Organization reports that the India Institute of Chemical Technology in Hyderabad, India and ILEX Oncology in Texas, United States are both working on new ways of making eflornithine more cheaply.

Eflornithine Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	intravenous	9084mg/kg/2W- (9084mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA	Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987.
man	TDLo	oral	800mg/kg/4D-I (800mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: THROMBOCYTOPENIA	Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 627, 1987.
women	LDLo	intravenous	67mg/kg/40M-C (67mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: PULSE RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	Annals of Internal Medicine. Vol. 105, Pg. 141, 1986.

Eflornithine Safety Profile

Human systemic effects by intravenous route: cardiomyopathy, pulse rate decrease, fall in blood pressure. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of F⁻ and NO_x.

Eflornithine Specification

Eflornithine , its cas register number is 70052-12-9. It also can be called Difluoromethylornithine ; Ornidyl ; Ornithine, 2-(difluoromethyl)- and a-Difluoromethylornithine .

Product Name

DFMO